Sweet syndrome following vemurafenib therapy for recurrent cholangiocarcinoma

Journal of Cutaneous Pathology

Volumn 41, Issue 3, 2014, Pages 326-328

  Pattanaprichakul, Penvadee ^a,b   Tetzlaff, Michael T ^b   Lapolla, Whitney J ^b   Torres Cabala, Carlos A ^b   Duvic, Madeleine ^b   Prieto, Victor G ^b   Tsai, Kenneth Y ^b   Curry, Jonathan L ^b  

^a MAHIDOL UNIVERSITY   (Thailand)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

neutrophilic dermatosis; toxicity; vemurafenib

Indexed keywords

INDOLE DERIVATIVE; SULFONAMIDE; VEMURAFENIB;

CHEMICALLY INDUCED DISORDER; FEMALE; HUMAN; MELANOMA; NEUTROPHILIC DERMATOSIS; NOTE; PANNICULITIS; PATHOLOGY; TOXICITY;

NEUTROPHILIC DERMATOSIS; TOXICITY; VEMURAFENIB;

FEMALE; HUMANS; INDOLES; MELANOMA; PANNICULITIS; SULFONAMIDES;

EID: 84894514269     PISSN: 03036987     EISSN: 16000560     Source Type: Journal    
DOI: 10.1111/cup.12273     Document Type: Letter

References (5)

1. Kim GH, Levy A, Compoginis G,. Neutrophilic panniculitis developing after treatment of metastatic melanoma with vemurafenib. J Cutan Pathol 2013; 40: 667.
2. Lacouture ME, Duvic M, Hauschild A, et al. Analysis of dermatologic events in vemurafenib-treated patients with melanoma. Oncologist 2013; 18: 314.
3. Monfort JB, Pages C, Schneider P, et al. Vemurafenib-induced neutrophilic panniculitis. Melanoma Res 2012; 22: 399.
4. Cohen PR,. Sweet's syndrome - a comprehensive review of an acute febrile neutrophilic dermatosis. Orphanet J Rare Dis 2007; 2: 34.
5. Shinojima Y, Toma Y, Terui T,. Sweet syndrome associated with intrahepatic cholangiocarcinoma producing granulocyte colony-stimulating factor. Br J Dermatol 2006; 155: 1103.